LAG-3抑制劑的全球市場:藥物銷售額與臨床試驗相關洞察(2029年)

Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Insight 2029

出版日期: 2024年06月01日 | 出版商:

KuicK Research | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

近年來，癌症治療出現了許多旨在提高現有治療效果的新方法。儘管取得了重大進展，但化學療法和放射療法等標準療法往往無法使許多癌症患者實現長期緩解或治癒。因此，研究人員將注意力轉向新的治療方法，其中一種針對免疫檢查點蛋白 LAG-3（淋巴細胞活化基因 3）。目前，有幾種 LAG-3 抑制劑正在進行臨床試驗，只有一種可以商業化，但由於全球癌症患者數量不斷增加，LAG-3 抑制劑市場正在迅速增長。增長。

LAG-3 是一種共抑制受體，存在於許多免疫細胞（包括 T 細胞和 NK 細胞）的表面。它的主要作用是控制免疫反應並防止過度激活，從而導致自體免疫疾病。然而，就癌症而言，腫瘤細胞可以利用 LAG-3 逃避免疫監視並抑制腫瘤細胞增殖和轉移。 LAG-3 的過度表現和上調存在於各種惡性腫瘤中，被認為有助於抑制抗腫瘤免疫反應，從而允許腫瘤生長和進展。這項發現為研究 LAG-3 作為癌症治療的有前景的治療標靶奠定了基礎。

美國和中國已成為 LAG-3 抑制劑領域的先驅，成為多種抑制劑的研發和臨床試驗中心。這是由於這些國家存在多家致力於LAG-3抑制劑開發的公司和研究機構，以及各自政府為製藥業創造有利環境所提供的持續支持。因此，LAG-3 抑制劑的版圖不斷擴大，包括歐盟、日本和韓國在內的許多其他國家為 LAG-3 抑制劑知識庫做出了重大貢獻。

本報告提供全球LAG-3抑制劑市場相關調查，提供市場概要，以及藥物趨勢，臨床試驗趨勢，各地區趨勢，及加入此市場的主要企業競爭情形等資訊。

Global LAG-3 Inhibitors Market Opportunity: > USD 3 Billion By 2029
Global & Regional Market Analysis
Commercially Approved LAG-3 Inhibitors: 1
Dosing, Pricing & Sales Insight On Approved LAG-3 Inhibitor
Insight On All LAG-3 Inhibitors In Trials: > 40
Global LAG3 Inhibitors clinical Trials Insight By Company, Country, Indication & Phase
Competitive Landscape: Insight on 15 Key Companies

In recent years, cancer treatment has witnessed a number of novel approaches aimed at improving the therapeutic effects of existing treatments. Despite substantial advances, standard therapies such as chemotherapy and radiation have frequently failed to achieve long-term remission or cure for a large number of cancer patients. As a result, researchers have focused on novel treatment approaches, one of which targets the immunological checkpoint protein LAG-3 (Lymphocyte Activation Gene-3). Several LAG-3 inhibitors are currently in clinical trials, and while only 1 is commercially available, the LAG-3 inhibitors market is expected to grow at an unprecedented rate in the coming years due to rising cancer cases worldwide and increased interest in this emerging drug class by pharmaceutical companies and researchers.

LAG-3 is a co-inhibitory receptor found on the surface of many immune cells, including T and NK cells. Its principal role is to regulate the immune response and prevent over-activation, which can lead to autoimmune diseases. However, in the setting of cancer, tumor cells can use LAG-3 to avoid immune surveillance, allowing them to grow and spread unabated. Overexpression and upregulation of LAG-3 have been seen in a variety of malignancies, and it is thought to contribute to the inhibition of anti-tumor immune responses, allowing tumor growth and progression. This discovery has laid the groundwork for investigating LAG-3 as a promising therapeutic target for cancer treatments.

In 2022, Bristol-Myers Squibb (BMS) made history when the US FDA authorized its medicine Opdualag, a fixed-dose antibody combination of relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) for the treatment of melanoma. The findings from the RELATIVITY-047 clinical trial were utilized to submit the Biologics License Application (BLA) for approval. This signified the regulatory approval of the first-in-class immune checkpoint inhibitor combination targeting LAG-3. Opdualag is currently approved in the US, the European Union, and a few other nations, with approval pending in a few more.

Opdualag has had a successful market debut, with revenues increasing quarter after quarter, indicating its therapeutic effectiveness and acceptance by both medical experts and patients. BMS reported total sales of more than US$ 600 million in 2023, and global sales of around US$ 200 million in the first quarter of 2024, a 76% increase over the same time in 2023. Furthermore, since its acceptance, the United States has regularly accounted for a sizable share of its revenue.

On the clinical front, numerous candidates are now in various levels of clinical development and evaluation, with Favezelimab and Fianlimab, developed by Regeneron and Merck, respectively, emerging as the LAG-3 inhibitors that have advanced the most in clinical studies. Both candidates are now undertaking many Phase 3 clinical trials for the treatment of various solid and hematological malignancies. In addition to these, Opdualag is also being tested in late-stage clinical trials in a variety of cancer indications, with melanoma subtypes accounting for a large portion of this.

Other companies, including Incyte Corporation, Xencor, Roche, Symphogen, and invoX Pharma, are also undertaking early-stage clinical trials for their prospective LAG-3 inhibitors, indicating that drug developers are becoming interested in this novel kind of immune checkpoint inhibitor. Many research institutions and universities have helped to further these clinical studies by serving as collaborators or trial sites. These include the Sidney Kimmel Comprehensive Cancer Center, Fudan University Shanghai Cancer Center, UPMC Hillman Cancer Center, Multiple Myeloma Research Consortium, Sun Yat-sen University, Emory University, University of California, and University of Colorado, among others.

The US & China have emerged as pioneers in the field of LAG-3 inhibitors, serving as research, development, and clinical trial hubs for several of these inhibitors. This can be attributed to the fact that these countries are home to several companies and research institutes working on the development of LAG-3 inhibitors, as well as the consistent support provided by their respective governments to create a favorable environment for their pharmaceutical industries. As a result, the landscape of LAG-3 inhibitors has expanded, with players from many other locations, including the EU, Japan, and South Korea, emerging as significant contributors to the LAG-3 inhibitor knowledge base.

In conclusion, LAG-3 has emerged as an intriguing therapeutic target in cancer, opening up new avenues for improving immunotherapy efficacy. Ongoing clinical trials, notably those looking at combination therapy with immunotherapies, are critical for determining the full potential of LAG-3 inhibition in lung cancer treatment. As the research advances, the future promises hope for more effective and individualized treatment choices, ultimately improving the prognosis and quality of life for those suffering from this deadly disease.

1. Introduction to LAG-3 Inhibitor

1.1 Overview Of LAG-3 inhibitor
1.2 Mechanism of Action
1.3 LAG-3 Targeted Therapy Approaches

2. Global LAG-3 Inhibitor Clinical Trials Overview

2.1 By Phase
2.2 By Country
2.3 By Company
2.4 By Indication
2.5 By Priority Status
2.6 Patient Segment

3. Global LAG-3 Inhibitors Market Scenario

3.1 Current Market Outlook (2022 Till Q1'2024)
3.2 Future Market Outlook (2024 - 2029)

4. LAG-3 Inhibitor Market Regional Analysis

4.1 South Korea
4.2 Australia
4.3 Canada
4.4 Japan
4.5 UK
4.6 Europe
4.7 China
4.8 US

5. LAG-3 Inhibitor Market Development By Indications

5.1 Lymphoma
5.2 Melanoma
5.3 Lung Cancer
5.4 Colorectal Cancer
5.5 Head & Neck Cancer
5.6 Esophageal Cancer

6. Opdualag (Nivolumab & Relatlimab-rmbw) - Overview, Pricing, Dosing & Sales Analysis

6.1 Overview
6.2 Pricing & Dosing
6.3 Sales (2022 Till Q1'2024)

7. Combination Stratagems for LAG-3 Inhibitors

8. Global LAG-3 Inhibitors clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III

9. Marketed LAG-3 Inhibitor Clinical insight

10. Global LAG-3 Inhibitors Market Dynamics

10.1 Market Drivers
10.2 Market Challenges

11. Competitive Landscape

11.1 Abeome Corporation
11.2 ABL Bio
11.3 Agenus
11.4 Akeso Biopharma
11.5 AnaptysBio
11.6 Bristol-Myers Squibb
11.7 EpimAb Biotherapeutics
11.8 F-star Therapeutics
11.9 Immutep
11.10 Incyte Corporation
11.11 Innovent Biologics
11.12 Merck
11.13 Roche
11.14 Shanghai Fosun Pharmaceutical
11.15 Y-Biologics

簡介目錄圖表

List of Tables

Table 3-1: China - Ongoing Clinical Trials for LAG-3 Inhibitors
Table 3-2: US - Some Ongoing Clinical Trials for LAG-3 Inhibitors
Table 4-1: Lymphoma - Some Ongoing Clinical Trials for LAG-3 Inhibitors
Table 4-2: Melanoma - Some Ongoing Clinical Trials for LAG-3 Inhibitors
Table 5-1: Opdualag - Maximum Infusion Volumes and Concentration Ranges by Patient Group
Table 5-2: Opdualag - Recommended Dosage Modifications for Adverse Reactions
Table 6-1: Ongoing Preclinical & Clinical trials for Combination of LAG-3 inhibitors

List of Figures

Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 12: LAG-3 Inhibitor - Mechanism of Action
Figure 1-3: Binding Efficacy of Bispecific Antibodies
Figure 2-1: Global - LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2024 - 2029
Figure 2-2: Global - LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2024 - 2029
Figure 2-3: Global - LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2024 - 2029
Figure 2-4: Global - LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2024 - 2029
Figure 2-5: Global - LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2024 - 2029
Figure 2-6: Global - LAG-3 Inhibitor Clinical Trials By Patient Segment (Numbers), 2024 - 2029
Figure 3-1: Global - LAG 3 Inhibitor Market (US$ Million), 2022 & 2023
Figure 3-2: Global - LAG 3 Inhibitor Market By Region(US$ Million), 2023
Figure 3-3:Global - LAG 3 Inhibitor Market By Region (%), 2023
Figure 3-4: Global - LAG 3 Inhibitor Market By Region (US$ Million), Q1'2024
Figure 3-5: Combination of Anti-LAG-3 Antibody with a Virus-Like Drug Conjugate (VDC), AU-011
Figure 3-6: Aspects Determining LAG-3 Inhibitor Future
Figure 3-7: Global - LAG 3 Inhibitor Market Forecast (US$ Million), 2024 - 2029
Figure 4-1 ABL501 Phase I (NCT05101109) Study - Initiation & Completion Year
Figure 4-2: Y Biologics Preclinical LAG-3 Candidate
Figure 4-3 NCT06259162 Study - Initiation & Completion Year
Figure 4-4 LBL-007 Phase I/II (NCT03744468) Study - Initiation & Completion Year
Figure 4-5 Relatlimab & Nivolumab Phase II (NCT05418972) Study - Initiation & Completion Year
Figure 4-6 Eftilagimod Alpha (IMP321) With Pembrolizumab Phase II (NCT03625323) Study - Initiation & Completion Year
Figure 4-7 Fianlimab & Cemiplimab Phase III (NCT05352672) Study - Initiation & Completion Year
Figure 4-8: Canada- Features Prompting LAG-3 Inhibitor Market
Figure 4-9: Relatlimab With or Without Nivolumab Phase I (NCT02966548) Study - Initiation & Completion Year
Figure 4-10: Relatlimab - Ongoing Studies Indication & Location Insights
Figure 4-11: Margetuximab in Combination With INCMGA00012 & Chemotherapy Phase II/III (NCT04082364) Study - Initiation & Completion Year
Figure 4-12: FS118 Phase I/II (NCT03440437) Study - Initiation & Completion Year
Figure 4-13: Europe Research Institutes & Hospitals Conducting LAG-3 Inhibitor Clinical Trials
Figure 4-14: INCAGN02385 & INCAGN02390 Phase II (NCT05287113) Study - Initiation & Completion Year
Figure 4-15: IMP321 with Immunotherapeutic/Targeted/Chemotherapeutic Agents Phase I (NCT03252938) Study - Initiation & Completion Year
Figure 4-16: Sym021 With Sym022 or Sym023 Phase I (NCT04641871) Study - Initiation & Completion Year
Figure 4-17: Tobemstomig with Atezolizumab, Bevacizumab & Tiragolumab Phase I/II (NCT05908786) Study - Initiation & Completion Year
Figure 4-18: AK129 Phase 1 (NCT05645276) Study - Initiation & Completion Year
Figure 4-19: LBL-007 Phase 1 (NCT04640545) Study - Initiation & Completion Year
Figure 5-1: Opdualag Phase 1/2 (NCT05255601) Study - Initiation & Completion Year
Figure 5-2: INCAGN02385 Phase 1 (NCT06290622) Study - Initiation & Completion Year
Figure 5-3: Favezelimab Phase 1/2 (NCT03598608) Study - Initiation & Completion Year
Figure 5-4: Fianlimab Phase 3 (NCT05352672) Study - Initiation & Completion Year
Figure 5-5: Fianlimab Phase 3 (NCT05608291) Study - Initiation & Completion Year
Figure 5-6: INCAGN02385 Phase 1/2 (NCT04370704) Study - Initiation & Completion Year
Figure 5-7: XmAb22841 Phase 1 (NCT05695898) Study - Initiation & Completion Year
Figure 5-8: Fianlimab Phase 2/3 (NCT05785767) Study - Initiation & Completion Year
Figure 5-9: Fianlimab Phase 2/3 (NCT05800015) Study - Initiation & Completion Year
Figure 5-10: Fianlimab Phase 2 (NCT03916627) Study - Initiation & Completion Year
Figure 5-11: Fianlimab Phase 2 (NCT06161441) Study - Initiation & Completion Year
Figure 5-12: HLX26 Phase 2 (NCT05787613) Study - Initiation & Completion Year
Figure 5-13: Favezelimab Phase 3 (NCT05064059) Study - Initiation & Completion Year
Figure 5-14: Fianlimab Phase 2 (NCT06205836) Study - Initiation & Completion Year
Figure 5-15: Relatlimab Phase 2 (NCT03642067) Study - Initiation & Completion Year
Figure 5-16: Relatlimab Phase 2 (NCT04080804) Study - Initiation & Completion Year
Figure 5-17: FS118 Phase 1/2 (NCT03440437) Study - Initiation & Completion Year
Figure 5-18: Tobemstomig Phase 1/2 (NCT04140500) Study - Initiation & Completion Year
Figure 5-19: Tobemstomig Phase 2 (NCT04785820) Study - Initiation & Completion Year
Figure 5-20: Relatlimab Phase 1 (NCT03044613) Study - Initiation & Completion Year
Figure 6-1: Opdualag - Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Date, 2024
Figure 6-3: US - Cost per Unit & Supply of Opdualag (US$), June'2024
Figure 6-4: EU - Cost per Unit & Supply of Opdualag (US$), June'2024
Figure 6-5: Global - Opdualag Annual Sales (US$ Million), 2022-2023
Figure 6-6: Global - Opdualag Sales by Region (US$ Million), 2023
Figure 6-7: Global - Opdualag Annual Sales by Region (%), 2023
Figure 6-8: Global - Opdualag Quarterly Sales (US$ Million), Q1'2024
Figure 6-9: Global - Opdualag Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 6-10: US - Opdualag Quarterly Sales (US$ Million), 2023
Figure 6-11: ROW - Opdualag Quarterly Sales (US$ Million), 2023
Figure 7-1: Overview to LAG-3 Combinations
Figure 10-1: LAG-3 Inhibitor - Market Drivers
Figure 10-2: LAG-3 Inhibitor - Market Challenges